Drugs / HS-10509
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06301074 | Mar → May 2024 | schizophrenia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-10509 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06301074 ↗ |
| Route | Oral | “will orally receive a single dose of HS-10509 or a matching placebo on Day 1” NCT06301074 ↗ |